#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodegenerative disorder Cutaneous T-cell lymphoma stage II Hypotransferrinaemia High-grade B-cell lymphoma Penile cancer Behcet's syndrome Infective uveitis Haemophilia B without inhibitors Endocrine ophthalmopathy Blastic plasmacytoid dendritic cell neoplasia Trigeminal neuralgia Chronic graft versus host disease Acute graft versus host disease in liver Follicular lymphoma Immune-mediated myositis More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Basic Information Antisynthetase syndrome – Life with Disease Hepatoblastoma – Diagnostics Chondrosarcoma metastatic – Treatment Mucous membrane pemphigoid – Trials in Disease Antisynthetase syndrome – Diagnostics Wiskott-Aldrich syndrome – Basic Information Medulloblastoma recurrent – Trials in Disease Nephroblastoma – Diagnostics Crigler-Najjar syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Aup1602-C Xenon (129Xe) Donanemab Pasireotide Diaspartate Caspofungin [18F]Fapi-74 ETX-19477 68Ga-Nota-Abscint-Her2 Dextromethorphan Hydrobromide Azithromycin Dihydrate Tulisokibart KETOROLAC TROMETAMOL Teplizumab Nipocalimab BENZYDAMINE HYDROCHLORIDE Eplontersen Tovorafenib GSK4418959A Inclisiran Sultiame More therapies…

    Learn about Your Condition

    Erythema Anxiety disorder Primary hypercholesterolaemia Asthma Breast cancer Synovitis Placenta praevia Primary myelofibrosis Clostridium difficile colitis Acute cardiac event Respiratory distress Pancreatitis chronic SAPHO syndrome Immunosuppression Asthmatic crisis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study of ODM-212 in Combination with Cancer Treatment for Patients with Advanced Solid Tumours

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Odm-212
    • Gemcitabine
    • Ipilimumab
    Denmark Finland France Spain

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Cabozantinib Monitoring for Toxicity Management in Patients with Renal Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    • Nivolumab
    Italy

  • Safety and Efficacy of Sodium Phenylbutyrate Eye Drops in Children with Myopia

    Recruiting

    2 1
    Investigated Diseases:
    • Myopia
    Investigated Drugs:
    • Sodium Phenylbutyrate
    Ireland

  • AMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Endocrine ophthalmopathy
    Investigated Drugs:
    • AMG 732
    France Italy Poland Spain

  • Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

    Recruiting

    3 1 1
    Investigated Drugs:
    • Remibrutinib
    Bulgaria Czechia France Germany Poland Spain
Previous Page
1 … 10 11 12 13 14 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!